II. Indications
III. Mechanism
- See Third Generation Broad-Spectrum Cephalosporin
- Good activity Gram Positive organisms
- Covers Staphylococcus Aureus
- Covers Pneumococcus
IV. Medications
- Suspension: 50 or 100 mg/5ml
- Stable for 14 days in refrigerator
- Tablets: 100 or 200 mg
- Take with food
V. Dosing
- Adult (and age >=12 years)
- Streptococcal Pharyngitis, Simple Urinary Tract Infection
- Take 100 mg orally twice daily
- Acute Exacerbation of Chronic Bronchitis, Community Acquired Pneumonia, Acute Sinusitis
- Take 200 mg orally twice daily
- Skin Infection
- Take 400 mg orally twice daily
- Streptococcal Pharyngitis, Simple Urinary Tract Infection
- Child (age <12 years)
- Give 5 mg/kg/dose orally twice daily
-
Renal Dosing
- eGFR <30 ml/min
- Decrease dosing frequency to every 24 hours
-
Hemodialysis
- Give after Hemodialysis 3 times per week
- eGFR <30 ml/min
VI. Safety
- Pregnancy Category B
- Safe in Lactation
VII. Drug Interactions
-
Antacids (reduce absorption)
- Take Cefpodoxime at least 2 hours before or 2 hours after
VIII. Resources
IX. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
- (2012) Presc Lett, Resource #280706, Comparison of Cephalosporins
Images: Related links to external sites (from Bing)
Related Studies
cefpodoxime (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
CEFPODOXIME 100 MG TABLET | Generic | $2.11 each |
CEFPODOXIME 200 MG TABLET | Generic | $2.66 each |
Ontology: cefpodoxime (C0055011)
Definition (NCI) | A third generation semi-synthetic cephalosporin and a beta-lactam antibiotic with bactericidal activity. Cefpodoxime's effect is dependent on its binding to penicillin-binding proteins (PBPs) located in the bacterial cytoplasmic membrane. Binding results in the inhibition of the transpeptidase enzymes, thereby preventing cross-linking of the pentaglycine bridge with the fourth residue of the pentapeptide and interrupting consequent synthesis of peptidoglycan chains. As a result, cefpodoxime inhibits bacterial septum and cell wall synthesis formation. |
Concepts | Antibiotic (T195) , Organic Chemical (T109) |
MSH | C053268 |
SnomedCT | 387534007, 96049003 |
LNC | LP15210-5, MTHU003033 |
English | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(methoxymethyl)-8-oxo-, monosodium salt, (6R-(6alpha,7beta(Z)))-, cefpodoxime, CEFPODOXIME, Cefpodoxime, Cefpodoxime (product), Cefpodoxime (substance) |
Spanish | cefpodoxima (producto), cefpodoxima (sustancia), cefpodoxima |
Ontology: Vantin (C0724204)
Concepts | Antibiotic (T195) , Organic Chemical (T109) |
MSH | C053267 |
English | Vantin, vantin |